Shandong Xinhua Pharma (00719) Sets 27 Mar 2026 Board Meeting to Review FY 2025 Results and Dividend Proposal

Bulletin Express

Mar 13

Shandong Xinhua Pharmaceutical Company Limited (stock code: 00719) has notified investors that its board of directors will convene at 9:00 a.m. on Friday, 27 March 2026, in the Company’s conference room at No. 1 Lutai Avenue, Hi-tech District, Zibo, Shandong, China.

The agenda comprises three items:

1. Approval of the audited consolidated results for the financial year ended 31 December 2025.

2. Consideration of a final dividend recommendation.

3. Discussion of any other business matters.

The meeting will be chaired by Mr. He Tongqing, with executive directors Mr. He Tongqing, Mr. Xu Wenhui and Mr. Hou Ning, four independent non-executive directors and two non-executive directors in attendance, as listed in the announcement.

The company released the notice on 13 March 2026. Investors should monitor subsequent disclosures for the finalised FY 2025 financial statements and any dividend decision.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1179374970"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1179374970\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1179374970?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-13 16:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1179374970","market":"us","top_or_hot":-1,"title":"Shandong Xinhua Pharma (00719) Sets 27 Mar 2026 Board Meeting to Review FY 2025 Results and Dividend Proposal","media":"Bulletin Express","content":"<p>Shandong Xinhua Pharmaceutical Company Limited (stock code: 00719) has notified investors that its board of directors will convene at 9:00 a.m. on Friday, 27 March 2026, in the Company’s conference room at No. 1 Lutai Avenue, Hi-tech District, Zibo, Shandong, China.</p>\n<p>The agenda comprises three items:</p>\n<p>1. Approval of the audited consolidated results for the financial year ended 31 December 2025.</p>\n<p>2. Consideration of a final dividend recommendation.</p>\n<p>3. Discussion of any other business matters.</p>\n<p>The meeting will be chaired by Mr. He Tongqing, with executive directors Mr. He Tongqing, Mr. Xu Wenhui and Mr. Hou Ning, four independent non-executive directors and two non-executive directors in attendance, as listed in the announcement.</p>\n<p>The company released the notice on 13 March 2026. Investors should monitor subsequent disclosures for the finalised FY 2025 financial statements and any dividend decision.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shandong Xinhua Pharma (00719) Sets 27 Mar 2026 Board Meeting to Review FY 2025 Results and Dividend Proposal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShandong Xinhua Pharma (00719) Sets 27 Mar 2026 Board Meeting to Review FY 2025 Results and Dividend Proposal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-13 16:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shandong Xinhua Pharmaceutical Company Limited (stock code: 00719) has notified investors that its board of directors will convene at 9:00 a.m. on Friday, 27 March 2026, in the Company’s conference room at No. 1 Lutai Avenue, Hi-tech District, Zibo, Shandong, China.</p>\n<p>The agenda comprises three items:</p>\n<p>1. Approval of the audited consolidated results for the financial year ended 31 December 2025.</p>\n<p>2. Consideration of a final dividend recommendation.</p>\n<p>3. Discussion of any other business matters.</p>\n<p>The meeting will be chaired by Mr. He Tongqing, with executive directors Mr. He Tongqing, Mr. Xu Wenhui and Mr. Hou Ning, four independent non-executive directors and two non-executive directors in attendance, as listed in the announcement.</p>\n<p>The company released the notice on 13 March 2026. Investors should monitor subsequent disclosures for the finalised FY 2025 financial statements and any dividend decision.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00719","symbol_name":"山东新华制药股份","start_time":0,"source_url":"","article_id":"1179374970","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1179374970","pubTimestamp":1773391483,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shandong Xinhua Pharmaceutical Company Limited (stock code: 00719) has notified investors that its board of directors will convene at 9:00 a.m. on Friday, 27 March 2026, in the Company’s conference...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"00719":"山东新华制药股份"},"translate_title":"山东新华制药(00719)定于2026年3月27日召开董事会审议2025财年业绩及股息建议","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00719":1},"content_text":"Shandong Xinhua Pharmaceutical Company Limited (stock code: 00719) has notified investors that its board of directors will convene at 9:00 a.m. on Friday, 27 March 2026, in the Company’s conference room at No. 1 Lutai Avenue, Hi-tech District, Zibo, Shandong, China.\nThe agenda comprises three items:\n1. Approval of the audited consolidated results for the financial year ended 31 December 2025.\n2. Consideration of a final dividend recommendation.\n3. Discussion of any other business matters.\nThe meeting will be chaired by Mr. He Tongqing, with executive directors Mr. He Tongqing, Mr. Xu Wenhui and Mr. Hou Ning, four independent non-executive directors and two non-executive directors in attendance, as listed in the announcement.\nThe company released the notice on 13 March 2026. Investors should monitor subsequent disclosures for the finalised FY 2025 financial statements and any dividend decision.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"conferences,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}